Here’s some good research from Israel supporting using cannabis for pain relief in cancer patients.
https://cannabisnews.com/news/29/thread29532.shtml
Cannabis for covid, I’ve been saying this for years. I vanquished the pesky virus in twenty four hours with the combination of CBD/THC applied everywhere I had pain or inflammation.
1 Like
Guardian survey into medical cannabis.
UK medical cannabis patients: tell us about your experiences with police | Cannabis | The Guardian.
1 Like
Down today probably because of the cock up by the FSA regarding CBD. Anyone who has knowledge of CBD and the potential health benefits it offers aren’t going to be limiting themselves to 10mg a day. So unless it becomes regulated then this is advisory but not backed by science.
I will post a link to a study in mice at a dose equivalent to 200mg per kilogram in humans, and we have different physiology.
So basically don’t chew down on hundreds or thousands of grams of pure CBD and all should be well 
Think the point you make is spot on. Anyone already using is not now going to reduce the dose,that shop has sailed.
Could do with a little positive bounce soon though although just bought a few more at 161 this morning.
Yes we could do with some upbeat news to lift the SP. CE mark would be very welcome just now.
1 Like
A helpful view on the regulatory model of medical cannabis in Belgium.
And on the share price, I think the fsa reaction was last week. I think this week’s dip may be a (strangely slow) reaction to the Israel Hamas war. Hopefully just me blowing off steam but I wouldnt be surprised if 2023 has more downhill action left in the tank. That said, even without the CE mark, the last rns was rock solid.
1 Like
Difficult isn’t it as I have more blind faith in this stock than any other I have for sone reason. So if we are to drop a tad more I think I’ll end up topping up and enjoy a prosperous 2024😬
1 Like
This stock and cellular will go down the route of mgc and consolidation soon 
1 Like
I can see the temptation to lump all cannabis related companies under the same bracket. But, MGC is an early stage pharma company and Cellular makes cream. Aside from the clear differences in what all three do, Kanabo are already chipping away at their debt.
It is gonna be a white knuckle ride for all three for the rest of 2023 that is for sure.
The only similarity I can see between the three companies is that they work with cannabinoids in the production of their goods.
For me it’s the quality of their products and the unique metered dose delivery method that singles them out. Even the recent FDA advice plays into their hands, with the advice being a 10mg limit per day Kanabo are the only company which offers a 1mg dose vape option, making regulating your intake very simple. Not that I agree with the FDA stance.
But KNB don’t just produce they take it to the market via the treat it clinic and the integrated GP service, the potential for growth is massive and the eventual introduction of cannabis to a broader market is coming. And we are perfectly positioned to take advantage of this.
On taking his position on the board of directors Ian Mattioli said it would take a year to see results and I am with him on this.
By next spring I am expecting to see this company begin its transformation into a highly profitable concern. I will be holding my position ATB.
France seem embattled on the medical cannabis topic. Good to see that the trial is continuing by my word, it seems to be a thorny issue due to a growing pressure of the right
2 Likes
Funny how the right are always wrong.
1 Like
I don’t have a choice not to hold regardless bought high I have to let it play out even if it liquidates AVG 0.22
Yes tough to be positive when you are that far down but I can’t see this one going under. Worst case scenario I would say is a buy out, they have too much going for them that would be attractive to a competitor.
GP service has lucrative business potential in it’s own right.
I am hoping for more than pennies when I do sell and am prepared to wait for the market to open up. As I have said before I had GWP @75p my first ever venture into shares. Impatience lack of knowledge of both the markets and no sufficiently clued up at the time about the potential of medical cannabis I sold under £ they got bought out @$77
Patience is key here IMO.
1 Like
2 Likes
Well our new none executive chairman is 50% down on his investment, will they take any action to support the share price?
It had been static for a while but now that is a grim start to a Friday
What can they reasonably do to support the share price ? A case of announcing further information or back it up from their end ?